[go: up one dir, main page]

MXPA04002490A - Interleucina-12 como adyuvante de vacuna veterinaria. - Google Patents

Interleucina-12 como adyuvante de vacuna veterinaria.

Info

Publication number
MXPA04002490A
MXPA04002490A MXPA04002490A MXPA04002490A MXPA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A
Authority
MX
Mexico
Prior art keywords
immunogenicity
enhancing
composition
immunoadjuvant
immunomodulator
Prior art date
Application number
MXPA04002490A
Other languages
English (en)
Inventor
Chu Hsien-Jue
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04002490A publication Critical patent/MXPA04002490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion describe una composicion para incrementar la inmunogenicidad de una vacuna veterinaria que comprende una cantidad farmacologicamente efectiva de un inmunorregulador y un inmunoadyuvante. Ademas, la descripcion describe una composicion de vacuna que comprende una un cantidad inmunizante efectiva de un antigeno, inmunorregulador, un inmunoadyuvante y un portador farmaceuticamente aceptable. Las composiciones pueden contener opcionalmente adyuvantes convencionales secundarios o conservadores. La invencion ademas describe un metodo unico para intensificar o acelerar la inmunogenicidad de antigenos marginalmente seguros, inmunosupresores o debiles al administrarle a una especie aviar o de mamifero, una cantidad farmacologicamente efectiva de la composicion intensificadora de la inmunogenicidad o una cantidad inmunizante efectiva de la composicion de vacuna anteriormente mencionada.
MXPA04002490A 2001-09-17 2002-09-13 Interleucina-12 como adyuvante de vacuna veterinaria. MXPA04002490A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32284001P 2001-09-17 2001-09-17
US10/243,075 US20030129161A1 (en) 2001-09-17 2002-09-12 Interleukin-12 as a veterinary vaccine adjuvant
PCT/US2002/029229 WO2003024354A2 (en) 2001-09-17 2002-09-13 Interleukin-12 as a veterinary vaccine adjuvant

Publications (1)

Publication Number Publication Date
MXPA04002490A true MXPA04002490A (es) 2004-05-31

Family

ID=26935571

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002490A MXPA04002490A (es) 2001-09-17 2002-09-13 Interleucina-12 como adyuvante de vacuna veterinaria.

Country Status (14)

Country Link
US (2) US20030129161A1 (es)
EP (1) EP1427349A4 (es)
JP (1) JP2005520786A (es)
KR (1) KR20040044942A (es)
CN (1) CN1555271A (es)
BR (1) BR0212556A (es)
CA (1) CA2457563A1 (es)
HR (1) HRP20040282A2 (es)
HU (1) HUP0500238A3 (es)
MX (1) MXPA04002490A (es)
NZ (1) NZ531526A (es)
PL (1) PL374123A1 (es)
WO (1) WO2003024354A2 (es)
YU (1) YU24004A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7347996B1 (en) 2002-06-26 2008-03-25 Intevert International B.V. Avian cytokines, such as IL-12, comprising a p40 and/or p35 subunit and vaccines
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
JP2007516968A (ja) * 2003-12-05 2007-06-28 ベクトン・ディキンソン・アンド・カンパニー 皮内コンパートメントにおける免疫応答を増強する方法、およびそれらの方法で有用な化合物
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
EP1928492B1 (en) * 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
EP2762163B1 (en) 2006-12-27 2018-01-03 Zoetis Services LLC Methods of vaccine administration
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009000066A1 (en) * 2007-06-22 2008-12-31 University Of Guelph Vaccine against clostridium perfringens
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
US8273122B2 (en) 2008-06-23 2012-09-25 Abbott Medical Optics Inc. Pre-loaded IOL insertion system
US8828675B2 (en) * 2009-11-20 2014-09-09 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
JP6267510B2 (ja) * 2010-05-18 2018-01-24 ニューメディシンズ，インコーポレーテッド 造血を増強するためのｉｌ−１２製剤
CN102908613A (zh) * 2011-08-04 2013-02-06 广州格拉姆生物科技有限公司 一种猪用免疫增强剂il-12b(p40)及其制备方法
KR102106762B1 (ko) 2012-10-11 2020-05-06 아박시스, 인크. 에를리히아 항체의 검출을 위한 펩티드, 장치, 그리고 방법
CN103028114A (zh) * 2012-12-28 2013-04-10 贵州大学 一种核酸疫苗、核酸疫苗免疫佐剂及制备方法
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CN104857511B (zh) * 2015-02-13 2018-03-30 浙江大学 含人参皂甙的疫苗稀释剂
US11382971B2 (en) 2015-09-09 2022-07-12 Tsinghua University Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) * 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US4894333A (en) * 1987-05-28 1990-01-16 Immunex Corporation Bovine interleukin-1α
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
MY111829A (en) * 1994-05-10 2001-01-31 Zoetis W Llc Modified live brsv vaccine
EP0784486B1 (en) * 1994-10-05 2006-04-05 Vanderbilt University Interleukin-12 as an adjuvant for paramyxoviridae vaccines
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5665347A (en) * 1995-02-02 1997-09-09 Genetics Institute IL-12 inhibition of B1 cell activity
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
ES2262181T3 (es) * 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
EP1053016A2 (en) * 1998-02-12 2000-11-22 American Cyanamid Company Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
AU6683400A (en) * 1999-07-08 2001-01-30 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat

Also Published As

Publication number Publication date
PL374123A1 (en) 2005-10-03
HUP0500238A3 (en) 2009-01-28
BR0212556A (pt) 2007-04-17
HUP0500238A2 (hu) 2005-05-30
EP1427349A4 (en) 2006-01-11
YU24004A (sh) 2006-08-17
JP2005520786A (ja) 2005-07-14
KR20040044942A (ko) 2004-05-31
WO2003024354A3 (en) 2004-02-05
WO2003024354A2 (en) 2003-03-27
US20080003201A1 (en) 2008-01-03
HRP20040282A2 (en) 2004-08-31
EP1427349A2 (en) 2004-06-16
US20030129161A1 (en) 2003-07-10
CN1555271A (zh) 2004-12-15
CA2457563A1 (en) 2003-03-27
NZ531526A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
IL174413A0 (en) Immunological adjuvants compounds
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
PT2364724E (pt) Composição de vacina compreendendo um adjuvante de saponina
HK1038507A1 (en) Influenza virus vaccine composition
GB0025577D0 (en) Vaccine
WO2002034119A3 (en) Vaccine immunotherapy for immune suppressed patients
YU8004A (sh) Vakcina protiv bolesti zapadnog nila
HU9601466D0 (en) Adjuvants for viral vaccines
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
HK1072264A1 (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
EP1395283A4 (en) HETEROLOGICAL PROTECTION, INDUCED BY IMMUNIZATION WITH THE INVAPLEX VACCINE
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2002009749A3 (en) Respiratory syncytial virus vaccine
AU3478393A (en) Vaccine containing acemannan as an adjuvant
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
WO2024155943A3 (en) Immunogenic compositions for african swine fever virus
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines
CY1114624T1 (el) Εμβολιο δυτικου νειλου

Legal Events

Date Code Title Description
FA Abandonment or withdrawal